Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
GSK and Sanofi shares surge after Florida ruling dismisses Zantac lawsuits in what one analyst describes as ‘best-case scenario'
06:06am, Wednesday, 07'th Dec 2022
Shares of pharmaceutical giants GSK PLC and Sanofi SA soared on Wednesday after what one analyst described as a “best-case scenario” Florida ruling that dismissed thousands of potential lawsuits o
GSK, Sanofi Shares Jump After U.S. Judge Dismisses Zantac Lawsuit
04:42am, Wednesday, 07'th Dec 2022
Tens of thousands of lawsuits alleged that the heartburn treatment could cause cancer. Complaints are still active in state courts.
GSK, Sanofi shares brighten as thousands of Zantac lawsuits are dismissed
04:17am, Wednesday, 07'th Dec 2022
Shares of GSK and Sanofi surged in early trading on Wednesday, following the dismissal of thousands of U.S. lawsuits claiming that the heartburn drug Zantac caused cancer.
GSK welcomes Zantac legal ruling in Florida
02:37am, Wednesday, 07'th Dec 2022
GSK has welcomed a US court ruling in a case which had claimed the Zantac heartburn drug caused cancer. The ruling by US district judge Robin Rosenberg in West Palm Beach, Florida, knocked out thousa
Haleon Proves Its Mettle After GSK Spinoff
06:17pm, Tuesday, 06'th Dec 2022
On July 18, GSK PLC ( GSK , Financial) completed the long-awaited spinoff of its consumer health care business, Haleon PLC ( HLN , Financial). By separating the slow but steady consumer health busines
These 3 Stocks Escaped Tuesday's Market Downdraft
05:11pm, Tuesday, 06'th Dec 2022
Even a dour outlook for the broader stock market couldn't outweigh good news for these companies.
Why GSK Plc And Sanofi SA Stock Are Shooting Higher - GSK (NYSE:GSK), Sanofi (NASDAQ:SNY)
04:20pm, Tuesday, 06'th Dec 2022
Shares of GSK plc GSK and Sanofi SA SNY are trading higher going into the close of Tuesday's session after the companies reportedly won a Zantac product liability lawsuit.
GSK's Myelofibrosis Candidate MAA Gets Accepted in Europe
12:02pm, Monday, 05'th Dec 2022
GSK's new drug application (NDA) for momelotinib is under standard FDA review, with a decision expected on Jun 16, 2023.
GSK gets price target cut from Citi as Zantac cloud lingers
04:52am, Friday, 02'nd Dec 2022
Analysts at Citi have lowered their price target for GSK PLC (LSE:GSK, NYSE:GSK) to 1,545p from 1,975p to reflect the limited visibility investors enjoy over the ultimate magnitude of Zantac ulcer
GSK delivers double dose of positive cancer drug news
03:51am, Friday, 02'nd Dec 2022
GSK PLC (LSE:GSK, NYSE:GSK) shares fell despite a double dose of positive news, with the EU medical regulator accepting its application for a myelofibrosis treatment and success in a Phase-3 endometri
GSK Phase 3 trial for Jemperli endometrial cancer treatment met primary endpoint
02:56am, Friday, 02'nd Dec 2022
GSK PLC said Friday that a Phase 3 trial for its Jemperli treatment for advanced or recurrent endometrial cancer met its primary endpoint, showing meaningful improvement in progression-free survival.
GSK plc (GSK) Presents at 5th Annual Evercore ISI HealthCONx Conference 2022
10:22am, Wednesday, 30'th Nov 2022
GSK plc (NYSE:GSK ) 5th Annual Evercore ISI HealthCONx Conference 2022 November 30, 2022 8:00 AM ET Company Participants Deborah Waterhouse - Chief Executive Officer, ViiV Healthcare Kimberly Smith -
PRO Watch DCLA's Sarat Sethi break down stocks to watch, markets
08:12am, Tuesday, 29'th Nov 2022
Sarat Sethi, managing partner and portfolio manager at DCLA, joins CNBC's 'Squawk Box' to break down potential market strategies and stocks to watch ahead of the open. Sethi also breaks down how he's
GSK to withdraw Blenrep's U.S. marketing authorization after FDA request
03:42am, Tuesday, 22'nd Nov 2022
GSK PLC GSK, +0.87% said Tuesday that it has started the withdrawal process of the U.S. marketing authorization for its Blenrep treatment, following the request of the country's Food and Drug Administ
GSK halts US marketing process for Blenrep after recent disappointing trial data
02:34am, Tuesday, 22'nd Nov 2022
GSK PLC (LSE:GSK, NYSE:GSK) has started for withdrawal process for US marketing authorisation for Blenrep following a request of the US Food and Drug Administration (FDA). The request followed th
